PBRM1 Loss-of-function

CI-VAR-00002538Explore in graph →CIViC 2705

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Biliary Tract Neoplasm1
PBRM1 Loss-of-function	Niraparib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12697 In biliary tract cancer (BTC) models with PBRM1 loss-of-function (EGI1 and CCC5), sensitivity to PARP inhibitors increased significantly, with lower IC50 values for niraparib (2.25 µM vs 6.62 µM, p = … (full text at CIViC) PMID 37400502 · Zimmer et al., 2023 · Open in CIViC	civic
Renal Cell Carcinoma4
PBRM1 Loss-of-function	Atezolizumab + DurvalumabSubstitutes	Predictive	B	Supports Sensitivity Response	3	submitted	EID7537 Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 63…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.